Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Ann Rheum Dis. 2019 Aug 22;78(11):1583–1591. doi: 10.1136/annrheumdis-2019-215208

Figure 1.

Figure 1

Upregulation and activation of IRF7 in SSc skin tissue. Five-micron thick skin tissue was stained with anti-IRF7 and p-IRF7 antibodies and immunostaining-positive cells (excluding nerve and endothelial cells) number in the dermis was counted in high power field. (A) Representative images. Dot plots with median (red +) and IQR (red −) shows IRF7-positive and p-IRF7-positive cell number inthe per high power field. Red arrows: IRF7 or p-IRF7 staining positive cells. n=10 per group; healthy control vs SSc; *p<0.01 (analysed by Mann-Whitney U test). (B) Immunofluorescence analysis using anti-IRF7 or p-IRF7 and α-SMA antibodies for IRF7-positive or p-IRF7-positive myofibroblast; anti-IRF7 or p-IRF7 and CD68 antibodies for IRF7-positive or p-IRF7-positive macrophages in the SSc and normal control skin. Representative images. Original magnifications: x400 magnifications. Scale bar: 125 μm. n=10. Arrows: IRF7 or p-IRF7 with α-SMA, or IRF7or p-IRF7 with CD68 double staining-positive cells. IRF7, interferon regulatory factor 7; α-SMA, α-smooth muscle actin; SSc, systemic sclerosis.